Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

Long-acting Cytokine Expressing Humanized Mouse Model Development Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Long-acting Cytokine Expressing Humanized Mouse Models Is Important for CART In Vivo Testing

Humanized mouse models play an important role in evaluating the drug safety and efficacy of immunotherapy. They have been widely employed due to their ease of use and good reproducibility. However, difficulties such as imperfect reconstruction of the human immune system hinder the development of humanized mouse models. Evidence suggests that expressing cytokines in humanized mice can help reconstruct humanized mouse models with fully human immune systems. Therefore, there is an urgent need to develop long-acting cytokine-expressing humanized mouse models.

Fig. 1 The application of humanized mouse models in CART.¹

Our Long-acting Cytokine Expressing Humanized Mouse Models for CART In Vivo Testing

To solve these obstacles, Creative Biolabs developed long-acting cytokine-expressing humanized mouse models for CART in vivo testing. We take advantage of long-acting cytokine delivery technology to construct humanized mouse models with complete immune systems, which promisingly enhance the ratio of myeloid cells and lymphoid cells in humanized mice. In this service, we provide a wide range of well-developed long-acting cytokine-expressing humanized mouse models for customers' immediate application. In addition, we provide several delivery strategies to deliver the target gene into the humanized mice. For the application of long-acting cytokine-expressing humanized mouse models into the evaluation of CART, we also offer some associated services, such as CART engineering, for your convenience in efficiently accomplishing your projects. At Creative Biolabs, we are confident in delivering the desirable outcomes for every client in a short turnaround.

Fig. 2 Vector development and in vivo CAR therapy.²

Delivery Strategies

We provide three common delivery strategies to help you introduce the desirable targets into humanized mice to develop appropriate humanized mouse models:

• Hydrodynamic Injection
• Pronuclear Injection
• Knock-In

Humanized Mouse Strains

Additionally, we provide several humanized mouse strains to choose from for the construction of humanized mouse models:

Published Data

DATA: The objective of this research endeavor was to examine the viability of utilizing anti-CD19 CAR-T cell therapy for the treatment of SLE in a murine disease model. By injecting the matching CAR-T cells into MRL-lpr mice, assessed the therapeutic efficacy of murine anti-CD19 CARs with CD28 or 4-1BB intracellular costimulatory motif. In addition, before the onset of the disease, anti-CD19 CAR-T cells were introduced into MRL-lpr mice to ascertain their potential function in the prevention of SLE. The results indicated that anti-CD19 CAR-T cell adoptive transfer resulted in a greater long-lasting reduction of B-cells in MRL-lpr mice compared to antibody therapy. In addition to preventing disease development, the transplantation of syngeneic anti-CD19 CAR-T cells also demonstrated therapeutic effects later in the course of the illness.

Fig. 3 The effectiveness of CAR-T cells in the mouse model of SLE.³

For more details about our long-acting cytokine-expressing humanized mouse models for CART in vivo testing, please feel free to get in touch with us.

References

1. Yue, Hanwei, and Lin Bai. "Progress, implications, and challenges in using humanized immune system mice in CAR‐T therapy—Application evaluation and improvement." Animal Models and Experimental Medicine (2023).
2. Michels, Alexander, et al. "Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms." Molecular Therapy (2022).
3. Jin, Xuexiao, et al. "Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus." Cellular & molecular immunology 18.8 (2021): 1896-1903.